Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Classical and alternative complement pathway activation in paracoccidioidomycosis

I T de Messias1, D Mohren

  • 1Department of Clinical Pathology, University Hospital, UFPR, Curitiba, Brazil.

Journal of Investigational Allergology & Clinical Immunology
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Immunocytochemical analysis of the inflammatory infiltrate in inclusion body myositis and other neuromuscular disorders with rimmed vacuoles].

Arquivos de neuro-psiquiatria·1998
Same author

Inhibition of the classical and alternative pathways of the human complement system by glycosaminoglycan polysulfate.

Journal of investigational allergology & clinical immunology·1994
Same author

Genetic variability of the MHC class III complement proteins C2, BF, C4A and C4B in southern Brazil.

Experimental and clinical immunogenetics·1994
Same author

Evaluation of complement activation in premature newborn infants with hyaline membrane disease.

European journal of pediatrics·1993
Same author

Complement levels and circulating immune complexes in a controlled, longitudinal, multicentre study on effects of intravenous immunoglobulin in adults with AIDS-related complex/Walter-Reed 5. The ARC-IVIG Study Group.

Vox sanguinis·1990
Same author

Complement activation in Brazilian pemphigus foliaceus.

Clinical and experimental dermatology·1989

This study shows that both the classical and alternative complement pathways are activated in paracoccidioidomycosis (PCM). Complement activation markers decreased with treatment, suggesting a role in disease activity.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Paracoccidioidomycosis (PCM) is a systemic fungal infection endemic to Latin America.
  • The role of the complement system in PCM pathogenesis is not fully understood.
  • Complement activation may contribute to the inflammatory response and disease progression in PCM.

Purpose of the Study:

  • To investigate the involvement of the classical and alternative complement pathways in patients with paracoccidioidomycosis.
  • To assess the correlation between complement activation markers and disease activity in PCM.
  • To evaluate changes in complement activation during treatment for PCM.

Main Methods:

  • Studied 28 untreated PCM patients from endemic areas in Brazil.
  • Assessed classical pathway activation using the C4d/C4 ratio.

Related Experiment Videos

  • Determined alternative pathway activation via rocket immunoelectrophoresis of fragment Ba.
  • Measured C3, C4, CH50, and anti-Paracoccidioides brasiliensis IgG levels.
  • Prospectively monitored complement markers in six patients during treatment.

    • Main Results:

    • Significantly elevated C4d/C4 ratios (classical pathway) in PCM patients compared to controls (p < 0.005).
    • Significantly higher Ba levels (alternative pathway) in PCM patients versus controls (p < 0.0005).
    • Decreased C4d/C4 ratio and Ba levels correlated with clinical improvement during treatment (p < 0.01).
    • Anti-P. brasiliensis IgG showed a weak positive correlation with C4d/C4 ratio (p < 0.03).
    • C3, C4, and CH50 levels did not significantly vary from normal ranges.

    Conclusions:

    • Both classical and alternative complement pathways are activated in paracoccidioidomycosis.
    • Complement activation is associated with PCM disease activity.
    • Monitoring complement activation may be useful for assessing treatment response in PCM.